Manufacturing

Articles

Distek, a provider of laboratory testing instruments, added a dual impeller single-use bioreactor (SUB) system to its BIOne portfolio.

Dual Impeller Single-Use Bioreactor

Barrett Fallentine is director of Product and Process Development, Pharmatech Associates, bfallentine@pai-qbd.com. 

Tech transfer is key to succession advancing biopharmaceutical pipeline products from research to preclinical.

Mind the Gap: Tech Transfer from Early Stage Cell Culture to Phase I Clinical Manufacture

MilliporeSigma’s use of modified amino acids can simplify the fed-batch process in biomanufacturing.

Using Modified Amino Acids to Simplify Fed-Batch Bioprocessing

Under the new long-term agreement, Sartorius Stedim Biotech will continue to offer Lonza media and buffer products under non-exclusive terms.

Lonza, Sartorius Stedim Biotech Modify Relationship for Supply of Cell-Culture Media

This article will explore the requirements for media and supplements needed to maintain newer cell lines, such as those based on human cells and fungal cells.

Media Requirements for Different Cell Sources

Cell-line quality has a significant impact on biologic drug quality; learn more about this and other upstream challenges at the new bioLIVE launching this year adjacent to CPhI Worldwide 2018.

Maintaining Cell-Line Integrity is Critical to Product Quality

New products were developed as next-generation process intensification technologies, MilliporeSigma reports.

MilliporeSigma Adds CEX Resin and Amino Acids

A collaboration integrates Sartorius Stedim Biotech’s BIOSTAT STR bioreactors and Repligen’s XCell ATF cell-retention control technology to create simplified, scalable equipment for intensified cell culture.

Sartorius Stedim Biotech and Repligen Corporation Partner to Introduce Perfusion-Enabled Bioreactors

Development costs and time to market continue to put pressure on the biopharma industry, driving the need for innovation in methods and technologies.

The Challenge of Building Better Biologic Drugs

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Biopharma seeks alternatives that meet the needs for next-gen biologic drug production.

Manufacturing, Cell Culture and Fermentation